ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs MXN
16.807
0.07%
Brent Oil
84.075
0.15%
Bitcoin
62,792.92
-0.41%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Lantern Pharma Inc (LTRN)

  7. Lantern Pharma Inc (LTRN) Noticias

LTRN

Lantern Pharma (LTRN)

Lantern Pharma Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:LTRN
FechaHoraFuenteTítuloSímboloCompañía
09/05/202415:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LTRNLantern Pharma Inc
09/05/202415:02Business WireLantern Pharma Reports First Quarter 2024 Financial Results and Business HighlightsNASDAQ:LTRNLantern Pharma Inc
06/05/202402:00Business WireOregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer MetabolismNASDAQ:LTRNLantern Pharma Inc
02/05/202406:30Business WireLantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
24/04/202407:00Business WireLantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug DevelopmentNASDAQ:LTRNLantern Pharma Inc
22/04/202407:12Business WireLantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and TaiwanNASDAQ:LTRNLantern Pharma Inc
18/03/202415:02Business WireLantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business HighlightsNASDAQ:LTRNLantern Pharma Inc
18/03/202406:12IH Market NewsAnticipation Builds on Wall Street for Federal Reserve’s Upcoming Policy Moves; WTI and Brent See UpticksNASDAQ:LTRNLantern Pharma Inc
15/03/202407:00Business WireLantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284NASDAQ:LTRNLantern Pharma Inc
11/03/202406:30Business WireLantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
05/03/202407:01Business WireLantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual ConferenceNASDAQ:LTRNLantern Pharma Inc
04/03/202407:01Business WireLantern Pharma's A.I. Platform, RADR®, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development TimelinesNASDAQ:LTRNLantern Pharma Inc
29/02/202420:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LTRNLantern Pharma Inc
15/02/202407:01Business WireLantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor CancersNASDAQ:LTRNLantern Pharma Inc
17/01/202406:30Business WireStarlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical OfficerNASDAQ:LTRNLantern Pharma Inc
29/12/202315:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LTRNLantern Pharma Inc
01/12/202305:02Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:LTRNLantern Pharma Inc
30/11/202307:00Business WireFDA Grants Lantern Pharma Orphan Drug Designation for Drug Candidate LP-284 in High-Grade B-cell Lymphomas (HGBL)NASDAQ:LTRNLantern Pharma Inc
08/11/202315:01Business WireLantern Pharma Reports Third Quarter 2023 Financial Results and Operational HighlightsNASDAQ:LTRNLantern Pharma Inc
01/11/202307:00Business WireLantern Pharma to Report Third Quarter 2023 Operating & Financial Results on November 8th, 2023 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
10/10/202307:00Business WireLantern Pharma to Present at the ThinkEquity Conference on October 19 at 1:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
03/10/202307:00Business WireLantern Pharma Announces Publication in Clinical Cancer Research Highlighting the Enhanced Efficacy of LP-184 in GlioblastomaNASDAQ:LTRNLantern Pharma Inc
25/09/202307:30Business WireLantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid TumorsNASDAQ:LTRNLantern Pharma Inc
18/09/202308:00Business WireLantern Pharma Receives IND Clearance from FDA Enabling Phase 1 Initiation for Drug Candidate LP-284 in Non-Hodgkin’s LymphomasNASDAQ:LTRNLantern Pharma Inc
31/08/202307:00Business WireLantern Pharma to Present Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-284 in Non-Hodgkin’s Lymphomas at the Society of Hematologic Oncology Annual MeetingNASDAQ:LTRNLantern Pharma Inc
28/08/202307:00Business WireLantern Pharma Expands AI Capabilities of RADR® Platform to Accelerate the Clinical Development of Immune Checkpoint InhibitorsNASDAQ:LTRNLantern Pharma Inc
14/08/202307:30Business WireLantern Pharma Receives Notice of US Patent Allowance for Drug Candidate LP-184 for the Treatment of Rare Pediatric Brain Cancer, ATRTNASDAQ:LTRNLantern Pharma Inc
09/08/202315:01Business WireLantern Pharma Reports Second Quarter 2023 Financial Results and Operational HighlightsNASDAQ:LTRNLantern Pharma Inc
02/08/202307:00Business WireLantern Pharma to Report Second Quarter 2023 Operating & Financial Results on August 9, 2023 at 4:30 p.m. ETNASDAQ:LTRNLantern Pharma Inc
17/07/202307:00Business WireLantern Pharma to Participate and Present at Multiple Upcoming ConferencesNASDAQ:LTRNLantern Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:LTRN

Su Consulta Reciente

COIN
ETHUSD
Ethereum
COIN
BTCUSD
Bitcoin
PM
XAUUSD
Gold vs US Dollar
USOTC
ADDYY
Adidas (QX)
NYSE
KO
Coca Cola
AMEX
SPY
SPDR S&P 500
NYSE
XOM
Exxon Mobil
CCOM
US500
US 500
USI
USTECH100
US Tech 100
AMEX
XLE
Energy Select Sector SPDR
NASDAQ
MSFT
Microsoft
FX
EURMXN
Euro vs MXN
CCOM
US30
US 30
NASDAQ
QQQ
Invesco QQQ Trust Series 1
FX
EURUSD
Euro vs US Dollar
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados